Posts Tagged ‘antiplatelets’

RSS

October 7th, 2013

Selections from Richard Lehman’s Literature Review: October 7th

This week’s topics include several papers on the CV safety of diabetes drugs, a follow-up report from the WHI on hormone therapy, clopidogrel and smoking, and more.


May 17th, 2012

FDA Approves Generic Clopidogrel as Plavix Loses Patent Protection

For the second time in the past 6 months, a cardiology mainstay drug has lost patent protection and gone generic. Today, the FDA announced that it had approved several generic versions of clopidogrel (Plavix), the antiplatelet drug that for many years was the second best-selling drug in the world. Last November, the best-selling drug of all time, […]


March 24th, 2012

Novel Antiplatelet Agent Reduces CV Events But Increases Bleeding

Vorapaxar, the novel antiplatelet agent from Merck, appears to effectively reduce cardiovascular death and ischemic events in patients with MI, ischemic stroke, or peripheral vascular disease, but its potential utility is clouded by bleeding complications, including intracranial hemorrhage. Results from the TRA 2P-TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial were presented […]